logo-loader

AstraZeneca’s new diabetes autoinjector pen approved by European regulators

Published: 08:15 30 Aug 2018 BST

bydureon
Astra has taken on board feedback from patients and doctors in its re-design of the pen

European regulators have approved AstraZeneca PLC’s (LON:AZN) Bydureon BCise once-weekly injection for the treatment of type-2 diabetes.

US authorities had already given the autoinjector pen the green light last October, and the European Commission has now followed suit.

READ: AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance

The new autoinjector features a simpler mixing process, a hidden needle, and a viewing window for users to confirm that they’ve received the medication.

Astra describes Bydureon Bcise as an “improved” version of its predecessor – which goes by the name Bydureon.

Clinical trials showed the device reduces blood sugar and contributes to weight loss.

“Building on the already well-established efficacy and safety profile of once-weekly Bydureon, today's approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise,” said VP late clinical development, Elisabeth Björk.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

2 hours, 45 minutes ago